IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
ConditionGastric Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRuijin Hospital
About this trial
This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Eligibility criteria
Qualifiers
1. Able and willing to sign a written Informed Consent Form (ICF) and to comply with protocol-specified visits and related procedures.
Disqualifiers
1. Has HER2-positive (defined as immunohistochemistry [IHC] 3+, or IHC 2+ and positive by in situ hybridization) disease.
Trial design
Treatments tested in this trial
- IBI343
- Sintilimab
- Oxaliplatin
- S-1
Treatment groups
55 Participants
are divided into 1 treatment groupSponsors and collaborators
Ruijin Hospital
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Collaborator
Source ClinicalTrials.gov